Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from India

This web-based study from India examined the frequency and characteristics of mucocutaneous reactions to COVID-19 vaccines. The majority (73.6%) of the respondents had received the Covishield vaccine (AstraZeneca-Oxford), while 26.4% had been vaccinated with Covaxin (Bharat Biotech-ICMR). Post-vaccination mucocutaneous effects were experienced by 87 (19.6%) participants. The most common mucocutaneous finding was a local injection site reaction, followed by urticarial rash, exacerbation of preexisting dermatoses, and other conditions. Anaphylaxis was reported in three individuals, but no fatalities were reported. The study concluded that the majority of reactions were mild and self-limiting, and these outcomes should not discourage people from getting vaccinated.